Brian Culley has been appointed as CEO of BioTime, succeeding co-CEOs Adi Mohanty and Michael West, PhD, the company announced in a press release.
BioTime, whose retinal restoration project has successfully grown complete human 3-D retinal tissue derived from human pluripotent cells, is working to address advanced retinal diseases and injuries.
Culley previously served as CEO at Mast Therapeutics, and his experience includes overseeing clinical development of pharmaceutical products from research through phase 3, corporate partnering and institutional capital raising, the release said.
“I
Uncategorized